Latest News

KSQ Therapeutics Announces Discovery of Gene Targets with Potential Activity Superior to PD-1 for Development of Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapies for Solid Tumors

CAMBRIDGE, Mass.–(BUSINESS WIRE)–KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced the identification and validation of a novel target, CT-1, for the development of engineered tumor infiltrating lymphocyte (eTIL™) therapies for refractory solid tumors. Data from two large-scale CRISPR-Cas9 functional screens using the com

Source link

Related posts

Alnylam, with positive data on second gene-silencing drug, plans filing to FDA


Researchers build 'mirror therapy' VR game to improve NHS patient experience


Ability of people with autism to infer mental states from faces may have been underestimated


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy